| scholarly article | Q13442814 |
| P50 | author | Fengcai Zhu | Q98952014 |
| Jingxin Li | Q124811772 | ||
| P2093 | author name string | Yang Zhou | |
| Xuefeng Zhang | |||
| Pengfei Jin | |||
| Xuejun Yao | |||
| Zhengkai Gan | |||
| Fangyue Meng | |||
| P2860 | cites work | Hand, foot, and mouth disease in China, 2008-12: an epidemiological study | Q33668897 |
| Clinical features, diagnosis, and management of enterovirus 71. | Q34144978 | ||
| Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 | ||
| Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. | Q34430200 | ||
| Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies | Q34609717 | ||
| Nomenclature for immune correlates of protection after vaccination | Q35948780 | ||
| Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial | Q36977606 | ||
| Evaluating a surrogate endpoint at three levels, with application to vaccine development | Q37107029 | ||
| Human enterovirus 71 epidemics: what's next? | Q37168703 | ||
| Correlates of protection to influenza virus, where do we go from here? | Q37384775 | ||
| Development of enterovirus 71 vaccines. | Q37682898 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine | Q38192021 | ||
| Update on the development of enterovirus 71 vaccines | Q38225695 | ||
| Review of enterovirus 71 vaccines | Q38263484 | ||
| Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia | Q39606586 | ||
| An inactivated enterovirus 71 vaccine in healthy children | Q40216677 | ||
| Surrogate endpoints in clinical trials: definition and operational criteria | Q41310696 | ||
| Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China | Q42226974 | ||
| Enterovirus vaccines for an emerging cause of brain-stem encephalitis | Q42226981 | ||
| Prediction of pertussis vaccine efficacy using a correlates of protection model | Q43527210 | ||
| Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children | Q43963300 | ||
| Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. | Q44566080 | ||
| Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 | ||
| A framework for assessing immunological correlates of protection in vaccine trials | Q48689937 | ||
| Correlates, surrogates, and vaccines. | Q54564614 | ||
| Risk Factors of Enterovirus 71 Infection and Associated Hand, Foot, and Mouth Disease/Herpangina in Children During an Epidemic in Taiwan | Q56879053 | ||
| Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines | Q57096715 | ||
| A model for immunological correlates of protection | Q81204629 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 916-921 | |
| P577 | publication date | 2016-01-11 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months | |
| P478 | volume | 12 |
| Q59355694 | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| Q54079810 | Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. |
| Q40230983 | Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5. |
| Q38840182 | Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine |
| Q57789471 | Estimating the Severity Profile of Enterovirus A71 Infections in Children: A Bayesian Synthesis Framework |
| Q40095911 | Identification of immune correlates of protection in Shigella infection by application of machine learning |
| Q96586665 | Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation |
| Q37688743 | Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment |
Search more.